The exchanges all have set parameters and some that are more flexible based on certain criteria. The $2 figure should be doable based on the revenue these companies have already done much less new lines of business.
Let us not forget AE37 isn't dead. What is the potential worth should it prove effective?
(0)
(0)
Generex Biotechnology Corp. (GNBTQ) Stock Research Links